Horizon Discovery and Mirna Therapeutics to Test Activities of Tumor Suppressor MicroRNAs
Horizon’s X-MANTM human cell lines will be used to define the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.
Advertisement
Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.
One of the challenges that cancer researchers face in developing cancer therapeutics is that of predicting which patient sub-groups will respond to future drug treatments. Horizon’s novel, genetically-defined X-MANTM human cell lines (or “patients-in-a-test-tube”) will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna’s miRNA mimics.
This project is funded in part by a Cancer Prevention and Research Institute of Texas (CPRIT) Commercialization grant.